ClinicalTrials.gg
RecruitingNCT06902896Updated Jul 14, 2026

Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy

A Phase 1/2 interventional study of FAP immunosuppressive CAR-DC in Dilated Cardiomyopathy (DCM) and Heart Failure, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
43
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Cardiomyopathy, Dilated with a site in China — 13 open to participants now, 14 under way, none of them phase 3. Cardiomyopathy, Dilated · China.

Planned enrollment
6th of 12
43 · median 43
Started
2025
with 2 others
Phase 1/2
2 of 23
1 open now
Primary completion
2028-06
later than 9 of 13 live
Registered
16th of 23
by date
Lead sponsor
3 of 23
Second Affiliated Hospital, School of Medicine, Zhejiang University

Among the 23 studies in Cardiomyopathy, Dilated with a site in China, this one is the 6th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2025, is one of 2 in phase 1/2, reaches primary completion later than 9 of the 13 other live ones, and was the 16th registered.

Cardiomyopathy, Dilated

256 studies on the registry are indexed under Cardiomyopathy, Dilated; 67 are open to participants now.

Browse Cardiomyopathy, Dilated studies →

Open to participants now

13 of the 23 studies in Cardiomyopathy, Dilated with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 54 Cardiomyopathy, Dilated studies recruiting now, 31 (57%) set no upper age limit and 15 (28%) stop at 75 or younger; 14 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Cardiomyopathy, Dilated with a site in China, or all of them as a file.
02

Study summary

To study the safety and efficacy of fibroblast activation protein (FAP)-targeted immunosuppressive chimeric antigen receptor-dendritic cell (CAR-DC) in the treatment of end-stage dilated cardiomyopathy and provide a new method for the treatment of end-stage dilated cardiomyopathy.

Read the detailed description

This study aims to evaluate the safety and efficacy of fibroblast activation protein (FAP)-targeted immunosuppressive chimeric antigen receptor-dendritic cell (iCDC) therapy in patients with end-stage dilated cardiomyopathy, and to provide a novel therapeutic approach for this condition. This is a prospective, single-center, open-label, two-phase clinical study designed to assess the safety and preliminary efficacy of iCDC in patients with end-stage dilated cardiomyopathy.

Phase 1 employs a single-arm, 3+3 dose-escalation design. iCDC therapy will be administered at predefined dose levels to evaluate safety, dose-limiting toxicities, treatment-related adverse events, and preliminary efficacy, and to determine the safe and effective dose.

Phase 2 will expand enrollment at the safe and effective dose identified in Phase 1. Additional patients will receive iCDC therapy at this dose, and a non-randomized concurrent control group will also be enrolled. Control participants must meet the same eligibility criteria and, after providing informed consent, choose not to receive iCDC therapy but agree to participate in study follow-up. They will not undergo leukapheresis, iCDC manufacturing, or cell infusion, and will continue to receive guideline-directed standard medical therapy. The iCDC treatment group will be assessed for safety and preliminary efficacy. The concurrent control group will be followed using clinically feasible shared assessments, including echocardiography, BNP or NT-proBNP, 6-minute walk distance, NYHA functional class, INTERMACS profile, KCCQ score, worsening heart failure, hospitalization, death, and major cardiovascular events. Cardiac magnetic resonance imaging and cell therapy-specific assessments will be performed exclusively in participants receiving iCDC therapy and will not be included in between-group comparisons with the control group.

03

Conditions studied

  • Dilated Cardiomyopathy (DCM)
  • Heart Failure

Keywords

  • end-stage dilated cardiomyopathy
  • FAP immunosuppressive CAR-DC
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 years old and 75 years old, diagnosed with dilated cardiomyopathy.
  • Able to verbally confirm that he/she understands the risks, benefits and treatment options of the iCDC trial. He/she or his/her legal representative provides written before participating in the clinical trial.
  • Diagnosed with Heart Failure with reduced (HFrEF), optimized drug therapy (under maximum tolerance of GDMT) for at least 3 months, left ventricular ejection fraction \<35%, functional class ⅢB-IV, INTERMACS class 3-6.
  • Blood test: hematocrit >30%, lymphocytes >0.5×10\^9/L, >60×10\^9/L.

Exclusion criteria

Exclusion Criteria:

  • History of myocardial infarction, unstable angina, stroke or within 12 weeks before enrollment.
  • CRT implanted within 12 weeks before enrollment or intended to implant CRT device.
  • Previous heart transplantation or implantation of a ventricular assist device or similar device, or planned implantation of a ventricular assist device or similar device.
  • Heart failure caused by ischemic cardiomyopathy, restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic (obstructive) cardiomyopathy, long-standing hypertension, congenital structural heart disease, or uncorrected primary valvular disease.
  • Symptomatic bradycardia or second/third degree heart block.
  • Active disease requiring therapy.
  • Pulmonary Embolism (PE).
  • A history of tuberculosis.
  • History of severe renal failure or need for dialysis, creatinine >2.5 mg/dl.
  • Uncorrected thrombocytopenia or systemic coagulopathy ( count \< 50,000, > 2.5, or aPTT > 2.5 times control in the absence of anticoagulation), or active bleeding and uncorrectable coagulopathy.
  • or alanine aminotransferase levels greater than 5.0 times the (ULN), total >3 mg/dl.
  • History of concurrent severe infection, hepatobiliary obstruction, or .
  • Infections: Active (PCR-detected hepatitis B virus DNA copies > 1000), , syphilis, or (HIV) infection at screening; uncontrolled systemic fungal, bacterial, viral, or other pathogen infection.
  • Severe hemodynamic instability (eg, shock).
  • Women who are pregnant or may become pregnant.
  • to study drugs or tests.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
43 participants (estimated)

Study arms

  • Experimental
    iCDC Therapy

    Participants in this arm will receive FAP-targeted immunosuppressive chimeric antigen receptor-dendritic cell (iCDC) therapy. In Phase 1, iCDC will be administered at predefined dose levels (1×10⁵, 4×10⁵, and 8×10⁵ cells/kg) using a modified single-arm 3+3 dose-escalation design. Safety and preliminary efficacy will be evaluated at each dose level. If a given dose level is deemed safe and effective at 1 month post-treatment, it will be selected as the safe and effective dose, and no further dose escalation will be pursued. Otherwise, dose escalation may proceed to the next predefined level in accordance with the protocol. In Phase 2, additional participants will receive iCDC therapy at the safe and effective dose identified in Phase 1.

    Biological: FAP immunosuppressive CAR-DC

  • No intervention
    Control

    Participants in this arm will be enrolled in Phase 2 as a non-randomized concurrent control group. They must meet the eligibility criteria and, after providing informed consent, elect not to receive iCDC therapy but agree to study follow-up. These participants will not undergo leukapheresis, iCDC manufacturing, or cell infusion, and will continue to receive guideline-directed standard medical therapy. They will be followed using clinically feasible shared assessments for exploratory comparison with the iCDC therapy arm.

Interventions

  • BiologicalFAP immunosuppressive CAR-DC

    Each subject receive FAP immunosuppressive CAR-DC by intravenous infusion

06

What researchers measure

Primary outcomes

  1. The proportion of subjects with Dose-limiting toxicity (DLT)

    The proportion of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: in 14 days after injection

  2. Incidence of treatment-emergent adverse events (TEAEs)

    Incidence of iCDC treatment-emergent adverse events

    Time frame: in 14 days after injection

Secondary outcomes

  1. Left ventricular ejection fraction (LVEF)

    The difference of LVEF from baseline. LVEF will be assessed by echocardiography.

    Time frame: 1, 3, 6, 12 months after injection

  2. Left ventricular ejection fraction (LVEF)

    The difference of LVEF from baseline. LVEF will be assessed by Cardiac Magnetic Resonance (CMR).

    Time frame: 6, 12 months after injection

  3. Enhanced volume (volume%)

    The difference of Enhanced volume (volume%) from baseline. Enhanced volume will be assessed by CMR.

    Time frame: 6 , 12 months after injection

  4. INTERMACS Profile

    Profile 1. Critical cardiogenic shock; Profile 2. Progressive decline on inotropic support; Profile 3. Stable but inotrope dependent; Profile 4. Resting symptoms home on oral therapy; Profile 5. Exertion Intolerant; Profile 6. Exertion Limited; Profile 7. Advanced NYHA Class III symptoms

    Time frame: 1, 3, 6 , 12 months after injection

  5. Left ventricular internal diameter end systole (LVIDs)

    The difference of LVIDs from baseline. LVIDs will be assessed by echocardiography.

    Time frame: 1, 3, 6 , 12 months after injection

  6. Left ventricular internal diameter end diastole (LVIDd)

    The difference of LVIDd from baseline. LVIDd will be assessed by echocardiography.

    Time frame: 1, 3, 6 , 12 months after injection

  7. Left ventricular end-systolic volume (LVESV)

    The difference of LVESV from baseline. LVESV will be assessed by CMR.

    Time frame: 6 , 12 months after injection

  8. Left ventricular end-diastolic volume (LVEDV)

    The difference of LVEDV from baseline. LVEDV will be assessed by CMR.

    Time frame: 6 , 12 months after injection

  9. NT-proBNP

    Analysis of differences of NT-proBNP serum level from baseline.

    Time frame: 1, 3, 6 , 12 months after injection

  10. 6 minutes walk test (6MWT)

    The difference of 6MWT from baseline.

    Time frame: 1, 3, 6 , 12 months after injection

  11. assessment of heart failure symptom

    The difference of heart failure symptom, which will be assessed by NYHA grading and KCCQ score.

    Time frame: 1, 3, 6, 12 months after injection

  12. Incidence of major adverse cardiovascular events (MACE)

    Incidence of Cardiac death, readmission due to heart failure.

    Time frame: 1, 3, 6, 12 months after injection

  13. incidence of adverse events

    Incidence of adverse events of heart, nerve system, mental system, digestive system and immune system.

    Time frame: 6, 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Jun 2028, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2025
First posted
Mar 30, 2025
StartActual
Apr 22, 2025
Primary completionEst.
Jun 30, 2028
CompletionEst.
Dec 31, 2028
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06902896
Responsible party
Sponsor
First posted
Mar 30, 2025
Start date
Apr 22, 2025
Primary completion
Jun 30, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jul 14, 2026

Study contacts

Jiamin Li, MD
Contact
21818216@zju.edu.cn
86-18868112006
Xinyang Hu, PhD
principal investigator · 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion